Journal article

A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases

Nicola S Meagher, Linyuan Wang, Peter F Rambau, Maria P Intermaggio, David G Huntsman, Lynne R Wilkens, Mona A El-Bahrawy, Roberta B Ness, Kunle Odunsi, Helen Steed, Esther Herpel, Michael S Anglesio, Bonnie Zhang, Neil Lambie, Anthony J Swerdlow, Jan Lubinski, Robert A Vierkant, Ellen L Goode, Usha Menon, Aleksandra Toloczko-Grabarek Show all

MODERN PATHOLOGY | NATURE PUBLISHING GROUP | Published : 2019

Abstract

Primary ovarian mucinous tumors can be difficult to distinguish from metastatic gastrointestinal neoplasms by histology alone. The expected immunoprofile of a suspected metastatic lower gastrointestinal tumor is CK7-/CK20+/CDX2+/PAX8-. This study assesses the addition of a novel marker SATB2, to improve the diagnostic algorithm. A test cohort included 155 ovarian mucinous tumors (105 carcinomas and 50 borderline tumors) and 230 primary lower gastrointestinal neoplasms (123 colorectal adenocarcinomas and 107 appendiceal neoplasms). All cases were assessed for SATB2, PAX8 CK7, CK20, and CDX2 expression on tissue microarrays. Expression was scored in a 3-tier system as absent, focal (1-50% of t..

View full abstract

Grants

Awarded by Cancer Research Society of Canada


Awarded by Cancer Institute NSW


Awarded by National Health and Medical Research Council of Australia


Awarded by US National Cancer Institute


Awarded by US Army Medical Research and Materiel Command


Awarded by NIH/National Center for Research Resources/General Clinical Research Center


Awarded by NATIONAL CANCER INSTITUTE


Funding Acknowledgements

This study is supported by research funds from Cancer Research Society of Canada (19319). NSM is supported by the NSW Ministry of Health and UNSW Sydney under the NSW Health PhD Scholarship Program, and the Translational Cancer Research Network, a translational cancer research center program funded by the Cancer Institute NSW. The Gynaecological Oncology Biobank at Westmead was funded by Cancer Institute NSW (12/RIG/1-17 and 15/RIG/1-16) and the National Health and Medical Research Council of Australia (ID310670, ID628903). FM is funded by University of Pittsburgh School of Medicine Dean's Faculty Advancement Award. The HOPE study is funded by: US National Cancer Institute (K07CA80668, P50-CA159981, R01CA095023), US Army Medical Research and Materiel Command (DAMD17-02-1-0669) and NIH/National Center for Research Resources/General Clinical Research Center (MO1-RR000056). KS is funded by the Swedish Cancer foundation. The Generations Study thank Breast Cancer Now, the Institute of Cancer Research and Ovarian Cancer Action for support and funding. The ICR acknowledge NHS funding to the NIHR Biomedical Research Centre. Tissue samples for GER were provided by the tissue bank of the National Center for Tumor Diseases (NCT, Heidelberg, Germany) in accordance with the regulations of the tissue bank and the approval of the ethics committee of the University of Heidelberg. The Health Science Alliance (HSA) Biobank acknowledges the UNSW Biorepository, UNSW Sydney, Australia. We thank Shuhong Liu, Young Ou, and Deon Richards for immunohistochemical stains, and Thomas Kryton, BFA, digital imaging specialist for Alberta Public Lab for creating the figures. We especially thank all the study participants, health care staff and data providers internationally who have made this research possible.